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Dengue Virus NS2B/NS3 Protease
Inhibitors Exploiting the Prime Side
Kuan-Hung Lin,* Akbar Ali, Linah Rusere, Djade I. Soumana,* Nese Kurt Yilmaz,
Celia A. Schiffer
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School,
Worcester, Massachusetts, USA
ABSTRACT The mosquito-transmitted dengue virus (DENV) infects millions of peo-
ple in tropical and subtropical regions. Maturation of DENV particles requires proper
cleavage of the viral polyprotein, including processing of 8 of the 13 substrate cleav-
age sites by dengue virus NS2B/NS3 protease. With no available direct-acting antivi-
ral targeting DENV, NS2/NS3 protease is a promising target for inhibitor design. Cur-
rent design efforts focus on the nonprime side of the DENV protease active site,
resulting in highly hydrophilic and nonspeciﬁc scaffolds. However, the prime side
also signiﬁcantly modulates DENV protease binding afﬁnity, as revealed by engineer-
ing the binding loop of aprotinin, a small protein with high afﬁnity for DENV pro-
tease. In this study, we designed a series of cyclic peptides interacting with both
sides of the active site as inhibitors of dengue virus protease. The design was based
on two aprotinin loops and aimed to leverage both key speciﬁc interactions of sub-
strate sequences and the entropic advantage driving aprotinin’s high afﬁnity. By op-
timizing the cyclization linker, length, and amino acid sequence, the tightest cyclic
peptide achieved a Ki value of 2.9 M against DENV3 wild-type (WT) protease. These
inhibitors provide proof of concept that both sides of DENV protease active site can
be exploited to potentially achieve speciﬁcity and lower hydrophilicity in the design
of inhibitors targeting DENV.
IMPORTANCE Viruses of the ﬂaviviral family, including DENV and Zika virus trans-
mitted by Aedes aegypti, continue to be a threat to global health by causing major
outbreaks in tropical and subtropical regions, with no available direct-acting antivi-
rals for treatment. A better understanding of the molecular requirements for the de-
sign of potent and speciﬁc inhibitors against ﬂaviviral proteins will contribute to the
development of targeted therapies for infections by these viruses. The cyclic pep-
tides reported here as DENV protease inhibitors provide novel scaffolds that enable
exploiting the prime side of the protease active site, with the aim of achieving bet-
ter speciﬁcity and lower hydrophilicity than those of current scaffolds in the design
of antiﬂaviviral inhibitors.
KEYWORDS dengue fever, Zika, antimicrobial peptides, antiviral agents, drug design,
protease inhibitors, receptor-ligand interaction, structural biology, substrate
Dengue virus (DENV), the causative agent of the disease dengue fever, is endemicin more than 110 countries, with approximately 390 million people infected yearly,
leading to about 20,000 deaths (1–3). Currently, no direct-acting antiviral drugs are
available either in clinics or in development to combat dengue virus infections. Thus,
a better understanding of the causative virus and potential viral drug targets is needed
to develop effective therapies.
DENV is a member of the family Flaviviridae and is an enveloped virus with a positive
single-stranded RNA genome. There are four different serotypes (DENV1 to DENV4), and
each serotype shares 65 to 70% sequence identity of the genome (4). The dengue virus
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RNA genome encodes a single polyprotein, which needs to get processed at the
cytoplasmic side of host cell rough endoplasmic reticulum membrane by dengue virus
NS2B/NS3 protease and at the luminal side by the host cell peptidase (5). Dengue virus
NS2B/NS3 protease is a serine protease that belongs to the chymotrypsin family with
a classic Ser-His-Asp catalytic triad (6). NS2B (amino acids 1394 to 1440), which is
referred to as a cofactor (cNS2B), is required for the proper function of NS3 protease
(NS3pro185; amino acids 1476 to 1660) (7) and participates in substrate recognition (8).
Dengue virus protease is responsible for the cleavage at 8 of the 13 polyprotein
cleavage sites (9). These cleavage steps are required for maturation of the viral particle,
making dengue virus NS2B/NS3 protease a promising target for drug development.
Inhibitors targeting dengue virus protease reported in the literature (10–14) have
largely been based on the P side of the substrate cleavage product, since the P1 and
P2 positions are rather conserved (basic amino acids), while the rest of the cleavage
sequences are diverse. While most of these inhibitors bind with only micromolar
afﬁnity, a recent study found inhibitors with nanomolar Ki values (15). However, the
potential challenge in targeting dengue virus protease is that this enzyme has a P side
substrate sequence preference similar to those of several human serine proteases (furin
RXRR, thrombin P1 R, and trypsin P1 R); hence, P side-based inhibitors are not designed
to be speciﬁc to the viral protease. Moreover, these linear peptide-derived inhibitors
have either low activity in enzymatic assays or substantially low potency in cellular
assays, probably due to high hydrophilicity (or low lipophilicity, commonly measured
by log octanol/water partition coefﬁcient [cLogP]) values caused by charged side chain
moieties at the P1 and/or P2 position. The relatively low afﬁnity and high hydrophilicity
and concerns for stability, combined with scarcity of small-molecule inhibitor-bound
crystal structures, have impeded further characterization and optimization of peptide-
based inhibitors.
The serine protease inhibitor aprotinin, a protein of 58 amino acids, has a high
afﬁnity for DENV protease and inhibits DENV2 protease with a Ki value of 26 nM (16).
The binding loop of aprotinin is highly analogous in sequence to the native NS3
cleavage site and spans from the P3 to P4= position at the active site of DENV protease
(8). By engineering the binding loop of aprotinin, we recently identiﬁed the optimal
amino acids for each of the P= positions (17). Ensuring speciﬁcity, the P= side of cleavage
products does not share homology with human serine protease substrates and includes
relatively hydrophobic amino acids. Our previous work determined that forming spe-
ciﬁc intermolecular interactions, such as hydrogen bonds contributed by P1 and P2=
residues, hydrophobic packing of P3= and P4= residues, and maintaining the confor-
mation of the aprotinin’s binding loop, is key for retaining binding afﬁnity (17).
In the current study, we leveraged the potency of aprotinin and our detailed analysis
of the speciﬁcity for dengue virus protease for P= side substrates to design the scaffold
for speciﬁc inhibitors. Building on the interactions identiﬁed to be key for binding, we
have designed cyclic peptides (CPs) targeting DENV protease active-site pocket from
the S3 to S4= position (Fig. 1). As we identiﬁed entropy to be the major driving force for
binding (17), a second aprotinin loop was incorporated into the design with the aim of
maintaining binding loop structure and rigidity. The binding loop of aprotinin (Pro13 to
Ile18/Ile19) and a second loop (Tyr35/Gly36 to Arg39) were linked together with or
without glycine spacers between Ile18/Ile19 and Tyr35/Gly36. The disulﬁde bond
between Cys14 and Cys38 already in aprotinin was kept to cyclize the peptide. The
inhibition constants of CPs against dengue virus protease were measured by ﬂuores-
cence resonance energy transfer (FRET)-based enzymatic assays, and molecular dynam-
ics (MD) simulations were applied to investigate the molecular interactions between
CPs and the protease active-site residues.
RESULTS
The measurable inhibition constants of cyclic peptides against DENV3 protease vary
from 2.9 M (CP7) to 780.3 M (CP9) (Tables 1 and 2). To determine the optimal length
of the cyclic peptide, peptides were designed with various lengths from the longest,
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CP1 and CP2 (residues P3 to P4=, two glycine linkers and residues 35 to 39), to the
shortest, CP12 (residues P3 to P3= and with no linker and residues 37 to 39).
First, the linker between the binding loop and second loop was optimized for
length. Comparing CP3 to CP5, or CP4 to CP7, no glycine linker is required between
Ile18 and Tyr35. Without the glycine linker, the inhibition improved, with Ki values
decreasing from 376.8 M to 14.5 M for CP3 versus CP5 and from 966.1 M to 2.9 M
TABLE 1 Inhibition constants for cyclic peptides of different lengths in enzymatic assays
against DENV3 NS3/2B proteasea
Peptide
Amino acid
Ki (M)
Fold
changeP3 P2 P1 P1= P2= P3= P4= 35 36 37 38 39
CP1 P C* K A R I I G G Y G G C* R 232.3 69.9 1.00
CP2 P C* K A R I I G G Y G G C* A 678.3 244.1 2.92
CP3 P C* K A R I G Y G G C* A 376.8 204.1 1.62
CP4 P C* R A R I G Y G G C* A 966.1 328.8 4.16
CP5 P C* K A R I Y G G C* A 14.5 6.7 0.06
CP6 P C* R A R I Y G G C* R 187.3 43.2 0.81
CP7 P C* R A R I Y G G C* A 2.9 0.8 0.01
CP8 P C* R A R I Y G C* A 467.9 68.7 2.01
CP9 P C* R A R I G G C* A 780.3 195.5 3.36
CP10 P C* R A R I G G C* R 29.7 5.8 0.13
CP11 C* R A R I Y G G C* R 145.1 27.9 0.62
CP12 P C* R A R I G C* A 101.2 24.8 0.44
aThe amino acid sequence is given based on corresponding substrate positions (P3 to P4=; aprotinin residues
12 to 18) and the linked aprotinin second-loop residue numbers (35 to 39). The peptides were cyclized
through a disulﬁde bond between cysteine residues indicated by an asterisk. The fold changes are relative
to CP1.
FIG 1 Design of cyclic peptides derived from aprotinin as dengue virus NS3/2B protease inhibitor. (A)
Aprotinin-DENV3 protease complex structure (PDB code 3u1j). The NS3 protease domain is in green, the
NS2B cofactor is in cyan, and aprotinin is in purple. (B) The binding loop and the second loop of aprotinin
on which the cyclic peptides were based are displayed as sticks. Dengue virus NS3/2B protease is shown
as a gray surface, and the catalytic triad is indicated by orange. (C) Cyclic peptide derived from aprotinin
is displayed as sticks. The amino acids (P3 to P3=) are numbered based on substrate residue positions. (D)
Hydrogen bonds between the cyclic peptide (magenta sticks) and dengue virus NS3/2B protease
(residues labeled and side chains depicted as green sticks) are displayed as yellow dashes. The catalytic
triad of protease is depicted as orange sticks, and residues are labeled.
Inhibitors of Dengue Virus Protease Journal of Virology
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for CP4 versus CP7. Further, comparing CP2 (Ki  14.5 M) to CP5 (Ki  678.3 M), P4=
isoleucine and two glycine residues as a linker were not favorable. Thus, no additional
linker residue is required to connect the two loops, and shorter cyclic peptides have
better inhibition against dengue virus protease.
Next, the optimal length of the second loop was investigated by comparing CP7 to
peptides with shorter second loops: For CP12, CP8, and CP9, the Ki values increased
from 2.9 M to 101.2 M, 467.9 M, and 780.3 M, respectively. Therefore, the optimal
number of residues for the second loop of the cyclic peptide between P3= Ile and Cys38
is three.
Optimizing residues for P1 and P2= positions of the peptides. Dengue virus
protease prefers basic residues lysine and arginine at the P1 position, and whether one
of these residues is preferred over the other was tested. CP3, with lysine at P1, has a
lower Ki (376.8 M) than does CP4, with arginine at P1 (966.1 M), but CP7, with
arginine at P1, has a lower Ki (2.9 M) than does CP5, with lysine at P1 (14.5 M) (Table
1). Thus, the preference between the two basic amino acids is subtle and context
dependent. While Arg can form one more hydrogen bond than can Lys, both residues
can form electrostatic interactions with the negatively charged residue D129 on the
protease. The charge interaction might be the dominant force in this pocket, explaining
the lack of a signiﬁcant difference between these two amino acids.
Arginine is favored at the P2= position and can form both a hydrogen bond and
more van der Waals (vdW) contacts than other residues, as we have previously shown
(17). In this study, arginine (large basic hydrogen bonding partner), glutamine (large
hydrophilic hydrogen bonding partner), and tryptophan (large aromatic hydrogen
bonding partner) at the P2= position were compared: CP7, CP14, and CP16 have Ki
values of 2.9, 1,273, and 145 M, respectively (Table 2). Glutamine of CP14, which can
also form a hydrogen bond, is less favorable at this position than arginine, and
tryptophan of CP16, which was designed to interact with protease through extensive
vdW contacts, is also less favored than that of CP7. These results reﬂect that both
hydrogen bonding and vdW contacts by the P2= residue are integral for the binding
interaction in this pocket.
The optimal C-terminal residue depends on the peptide length. To decrease the
ﬂexibility at the C terminus of the cyclic peptides, the long side chain of Arg39 (present
in native aprotinin sequence) was replaced with alanine. The CP1 peptide, which is
longer with linkers between the binding and second loop, has an arginine at this
position (Ki  232.3 M). The inhibition was weaker when the arginine was replaced
with an alanine (CP2; Ki  678.3 M). In contrast, comparing CP6, with an arginine, to
CP7, with an alanine, the afﬁnity improves, with the Ki value dropping from 187.3 M
to 2.9 M (Table 1). Thus, decreased ﬂexibility at the peptide C terminus was beneﬁcial
TABLE 2 Inhibition constants for cyclic peptides with sequence optimization against
DENV3 NS3/2B proteasea
Peptide
Amino acid
Ki (M) Fold changeP3 P2 P1 P1= P2= P3= 35 36 37 38 39
CP7 P C* R A R I Y G G C* A 2.9 0.8 1.00
CP13 Bzb C* R A R I Y G G C* A 33.2 6.5 11.45
CP14 P C* R A Q I Y G G C* A NBc NB
CP15 P C* R A W I Y G G C* R 19.7 8.8 6.79
CP16 P C* R A W I Y G G C* A 144.8 54.4 49.93
CP17 P C* R A R I D G G C* A 69.3 24.4 23.90
CP18 P C* R V R I D G G C* A 35.8 16.4 12.34
CP19 P C* R V R I Y G G C* A 25.6 9.9 8.83
aThe amino acid sequence is given based on corresponding substrate positions (P3 to P4=; aprotinin residues
12 to 18) and the linked aprotinin second loop residue numbers (35 to 39). The peptides were cyclized
through a disulﬁde bond between cysteine residues indicated by an asterisk. The fold changes are relative
to CP7.
bBz denotes benzoyl capping group.
cNB, no binding.
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for tighter binding interactions at this peptide length. When the peptide length was
further decreased by removing Tyr35, the trend was reversed: CP10, with an arginine,
had better inhibition (Ki  29.7 M) than did CP9, with an alanine (Ki  780.3 M).
Potentially in these smaller peptides without Tyr35, the binding conformation is altered
and the terminal arginine interacts with the S2= pocket, speciﬁcally with Asp75,
resulting in the observed lower Ki value. Overall, the length of the peptide likely
determines the position of the terminal residue when bound to dengue virus protease
active site, resulting in peptides with different lengths favoring different amino acids at
this position.
N-terminal capping. To investigate the contribution of P3 residue (N terminus), the
proline at this position was replaced with a benzoyl capping group, which can mimic
interactions contributed by the proline ring. CP13 with the capping group has a higher
Ki value (33.2 M) than does CP7 (2.9 M), indicating that proline is more favorable
than a benzoyl group (Table 2). Further, to investigate the requirement of a P3 residue,
we designed CP11, which does not have the P3 residue. Comparing CP6 and CP11,
removal of the whole proline residue did not signiﬁcantly change the Ki values, which
suggests, at least in this context, that P3 proline is not required (Table 1).
Cyclic peptide inhibitors are ﬂexible. Based on the Ki values of the cyclic peptides
designed and assayed, both the sequence and length of the cyclic peptide signiﬁcantly
affect binding to dengue virus protease. However, the Ki values are still much higher
(lower inhibition activity) than the same peptide sequence within the binding loop of
aprotinin. We have shown through isothermal titration calorimetry (ITC) that entropy is
the driving force for binding of aprotinin and variants, and ﬂuctuations in molecular
dynamics (MD) simulations correlate with binding afﬁnity for aprotinin constructs (17).
To investigate how the dynamics of cyclic peptide molecular interactions compare to
those within the context of aprotinin constructs, MD simulations of the highest-afﬁnity
cyclic peptide bound to dengue virus protease were carried out. MD simulations started
from the protease structure with the CP7 peptide modeled into the binding pocket
based on the aprotinin-DENV3 protease complex structure (PDB code 3u1j). The
dynamics were compared to those of the aprotinin-protease complex structure (3u1j)
to examine whether interactions important for aprotinin binding were still maintained.
Throughout the simulation, the CP7 cyclic peptide remained positioned in the
binding site. Snapshots of CP7, and the corresponding binding loop/second loop with
the same sequence within aprotinin (the simulation included the whole aprotinin, but
only these loops are displayed), are shown in Fig. 2. Both the superimposed snapshots
and calculated root-mean-square ﬂuctuation (RMSF) values of the backbone indicate
FIG 2 Molecular dynamics (MD) simulations of aprotinin and the cyclic peptide CP7 bound to the dengue virus protease active
site. (A) Snapshots from MD simulation trajectories of aprotinin and CP7 bound to DENV3 protease. The protease is depicted
in cartoon representation in green and the aprotinin’s binding/second loops or CP7 as sticks from the start (in red) to the end
(in blue) of the trajectory. (The simulations were performed with full-length aprotinin, but only residues corresponding to
native substrates are shown for clarity.) (B) The RMSF values during MD simulations were tabulated as the average for the
binding loop and the second loop and are displayed for individual residue positions.
Inhibitors of Dengue Virus Protease Journal of Virology
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that the binding loop and second loop are more ﬂexible in CP7, with 0.7-Å- and
1.6-Å-higher RMSF values than for the corresponding loops within the context of
aprotinin, respectively. The second loop of CP7 was incorporated with the aim of
sustaining the binding loop structure and providing some of the rigidity observed in
aprotinin; however, these results illustrate that the cyclic peptide, although still stable
in the binding site, is relatively more ﬂexible. The decreased rigidity of the cyclic
peptide compared to aprotinin correlates with the loss in potency.
Cyclic peptide maintains contacts with DENV protease. To investigate how the
cyclic peptide inhibitor packs against the protease active site, both the intermolecular
vdW contacts and the hydrogen bonding patterns were analyzed. The average vdW
contact energy of each binding loop residue was calculated throughout the simulation
time (Fig. 3). Similar to the contacts of same positions within the aprotinin binding loop
(17), P1 Lys/Arg and P2= Arg contribute the most contact energies. Intermolecular
contacts are formed by P3-P3= residues, with the only other residue beyond this region
making contact with the protease being the side chain of Cys38 in the disulﬁde bond.
Overall, the rest of the residues in CP7 P3-P3= make similar contacts at each corre-
sponding position as in the aprotinin binding, but the total vdW contact is slightly
decreased. The intermolecular hydrogen bonds formed by the binding loop residues
were also analyzed and compared to those in aprotinin (Table 3). The hydrogen bonds
that are observed for aprotinin binding to the protease are conserved in the cyclic
peptides; however, these hydrogen bonds are more stable in aprotinin, existing for a
larger percentage of the simulation time. As these binding loops within aprotinin and
within the cyclic peptide have the same sequence (except the P1 residue, lysine or
FIG 3 Average intermolecular van der Waals (vdW) contact energies during MD simulations between
aprotinin or CP7 binding loop residues and DENV3 protease.
TABLE 3 Hydrogen bonds between residues of aprotinin or cyclic peptides and DENV3
protease and the percentage of time the hydrogen bonds existed during the MD
simulationsa
aYellow highlights values higher than 40%, and red highlights values higher than 60%.
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arginine), the differences in vdW contacts and hydrogen bonding tightness likely reﬂect
how stable the whole macrocyclic peptide is within the binding pocket.
Targeting Arg54 on the protease. To further increase the speciﬁcity of the cyclic
peptide, potential interactions of the cyclic peptide were assessed. Arg54 of dengue
virus protease is conserved throughout all four serotypes of dengue virus, is a lysine in
both West Nile virus (WNV) and Zika virus, but is not conserved in human furin,
thrombin, or trypsin. To build interactions with this particular residue and thus poten-
tially enhance speciﬁcity, various residues on the second loop of the cyclic peptides
were replaced with acidic residues. Replacing Tyr35 with aspartic acid in both CP17
(with an alanine at P1=) and CP18 (valine at P1=) resulted in Ki values of 69.3 M and
35.8 M, respectively (Table 2). While P1= alanine is more favorable over valine (comparing
CP7 to CP19), there is no signiﬁcant difference between alanine and valine with Asp35.
Since the S1= pocket is relatively small, alanine may ﬁt better than valine in this pocket.
However, the P1= valine may push the second loop closer to Arg54 on the protease,
stabilizing the interaction between Asp35 of cyclic peptide and Arg54 of the protease.
The interactions we aimed to stabilize between these two residues would be reﬂected
by an extra hydrogen bond between this cyclic peptide-protease pair.
To test whether this design achieved this extra hydrogen bond, CP17 was modeled
and MD simulations were performed on CP17 bound to dengue virus protease to
investigate the dynamics of molecular interactions between Asp35 of cyclic peptide
and Arg54 of the protease. Similar to the simulations of the tightest binder CP7, MD
simulations started from the protease structure with the CP17 peptide modeled into
the binding pocket based on the aprotinin-DENV3 protease complex structure (PDB
code 3u1j) (8). For the peptide CP17, there is one extra hydrogen bond formed between
Asp35 of CP17 and Arg54 of the protease (Table 3), which is promising. As Arg54 on the
protease is conserved in the ﬂaviviral proteases, further optimization of interactions
with this residue is a potential strategy to increase the speciﬁcity of these peptides
against dengue virus protease.
DISCUSSION
In this study, we designed cyclic peptide inhibitors targeting both P and P= sites of
dengue virus protease and optimized the sequence and length of these peptides. The
best binder (CP7) has a Ki value of 2.9 M against DENV3 wild-type (WT) protease. These
inhibitors were derived based on the binding loop of aprotinin, and as intended,
interactions important for aprotinin binding were preserved, speciﬁcally the hydrogen
bonds contributed by P1 and P2= residues and vdW contacts of each residue position.
However, these interactions in the cyclic peptides were not as strong as those in
aprotinin upon binding to dengue virus protease. The MD simulations and the resulting
RMSF values reﬂect that even though a second loop was included in the design to
support the structure and stability of the binding loop, the cyclic peptide is still more
ﬂexible than the corresponding loops in aprotinin. This increased ﬂexibility may ac-
count for the decreased afﬁnity between the cyclic peptides and protease, which
explains why these cyclic peptides have higher Ki values against DENV3 WT protease
than aprotinin. Nevertheless, these peptides demonstrate the proof of principle and
viability of targeting the primed side of the DENV3 protease active site as a potential
strategy for speciﬁc inhibition. A similar strategy of inhibitor design based on aprotinin
was applied to WNV protease (18), indicating that cyclic peptide derived from aprotinin
can be a promising scaffold for inhibitor design targeting serine proteases.
To move these inhibitors from proof-of-principle micromolar inhibitors to poten-
tially viable antiviral drugs, many other additional strategies are needed to further
increase the afﬁnity. The ﬁrst such strategy is to increase the rigidity. The two loops of
cyclic peptide inhibitor (CP7 as an example) are linked together through a peptide
bond between Ile18 and Tyr35, and a disulﬁde bond between Cys14 and Cys38 (Fig. 1;
Tables 1 and 2), which could be broken under reducing conditions, including in the
cellular environment. Using a nonreducible covalent bond instead is a strategy to
increase the stability of the cyclic peptide, or incorporating heterocycles at the same
Inhibitors of Dengue Virus Protease Journal of Virology
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position is a strategy to increase both stability and rigidity. Incorporating heterocycles
between the binding loop and second loop of cyclic peptides at different positions
could be another strategy to rigidify the peptides, as could replacing one or more
peptide bonds with more rigid nonrotatable bonds. The second strategy for increasing
the afﬁnity is to decrease the molecular weight of the cyclic peptide by cutting residues
at both termini. The third strategy is to target the hydrophobic protease residues 30
and 31, which deﬁne the S4= pocket and were proposed to interact with the membrane
(19, 20). The fourth strategy is to couple the prime side inhibitors with P site inhibitors,
which are generally highly charged and polar, to potentially increase their cell perme-
ability. The ﬁfth strategy is to replace the peptide bond between P1 and P1= residues
with a noncleavable bond, which would be beneﬁcial to the integrity of the cyclic
peptide. Replacing the carbonyl group of P1 residue, which forms a key hydrogen bond
with protease’s Ser135 backbone amide nitrogen (Fig. 1D and Table 3), with peptide
bioisosteres such as reduced amide, ketoethylene, or hydroxyethylene, the hydrogen
bonds can be maintained while making the bond noncleavable. A viable high-afﬁnity
inhibitor may be attainable by combining one or more of these strategies to form a
more rigid cyclic inhibitor.
Macrocyclic inhibitors were shown to successfully inhibit hepatitis C virus (HCV)
NS3/4A protease compared to their linear analogs, and these inhibitors were
cyclized through links between side chains (21), unlike through-backbone bonds in
dengue virus cyclic peptides. Since dengue virus protease’s S2= and S4= pockets are
solvent exposed and overlapping (Fig. 1C), similar to the S4 and S2 pockets of HCV
NS3/4A protease, introducing a P2=-P4= macrocycle to these cyclic peptides can
potentially increase both peptide rigidity and the packing against residues in these
two pockets.
Recently, DENV/WNV protease inhibitors targeting P site pockets with nanomolar
activity in enzymatic assays have been reported (Ki  12 nM and 39 nM) (15). Since
these inhibitors are highly polar, possibly underlying the micromolar-level activity in
cell-based assays, incorporating the critical hydrophobic interactions we identiﬁed at
P3= or P4= pockets (17) is a strategy to reduce the hydrophilicity. Further, building
interactions with the conserved DENV protease residue Arg54 could increase the
speciﬁcity of this tighter-binding lead compound. Unnatural amino acids such as Orn
at the P1 position instead of Lys to maintain critical polar interactions without
distributing the charge, or halogenated amino acids to exploit halogen bonding,
can be used in the future improvement of these compounds. A crystal structure of
DENV protease bound to a lead compound spanning both P and P= sides would be
immensely useful for further optimization in the design of more potent and speciﬁc
inhibitors. In the future, further improvement of P2 and P3 moieties, such as those
in a peptide-based inhibitor with an available crystal structure (PDB code 3U1I),
could leverage additional interactions with the NS2B cofactor. Lastly, as dengue
virus protease shares substrate sequence similarity with other ﬂaviviral proteases
causing human infections, notably Zika virus protease, the lead compounds and
strategies identiﬁed in this study can lead to the design of pan-ﬂaviviral inhibitors
or inhibitors targeting other ﬂaviviruses.
MATERIALS AND METHODS
Protein and peptides. The DENV protease gene (cDNA encoding NS2B cofactor [cNS2B; amino acids
1394 to 1440] and NS3 protease [NS3pro185; amino acids 1476 to 1660] with a G4SG4 linker in between)
was constructed for protein expression in Escherichia coli, as described previously (8). The protease gene
was constructed between BamHI and XhoI sites of plasmid pGEX6p1 (GE Healthcare), and BL21(DE3) cells
were used for protein expression. Published protein expression and puriﬁcation protocols were used (22).
All cyclic peptides were purchased from 21st Century Biochemicals.
Enzyme inhibition assay. A ﬂuorescence resonance energy transfer (FRET)-based enzymatic assay
was used to determine the inhibition constants of cyclic peptides against DENV3 WT protease. A 100 nM
concentration of the DENV3 protease was incubated with various concentrations of cyclic peptides (5
mM to 500 nM) for 60 min in 50 mM Tris assay buffer {20% glycerol, 1 mM 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate [CHAPS]; pH 8.5} (23). A 5 M concentration of protease
substrate [Ac-[D-EDANS]KRRSWP[K-DABCYL]-AMIDE] (21st Century Biochemicals) was added to ini-
tiate proteolysis and monitored using the EnVision plate reader (PerkinElmer) at excitation and emission
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wavelengths of 340 nm and 490 nm, respectively. One-phase association nonlinear ﬁt to the whole
progress curve was applied to determine the initial cleavage velocities (24). By nonlinear regression
ﬁtting to the Morrison equation of initial velocity versus inhibitor concentration using Prism 6
(GraphPad Software), apparent inhibition constants (Ki) were obtained. Data were collected in
triplicate and processed independently to calculate the shared inhibition constant and standard
deviation.
Molecular dynamics simulations. All molecular dynamics simulations were performed in triplicate
by following previously published protocols (25). To prepare the modeled complex structures, the
aprotinin-bound DENV3 WT protease structure (PDB code 3u1j) was used as a starting point. Aprotinin
residues except the binding loop (Pro13 to Ile18/Ile19) and the second loop (Tyr35/Gly36 to Arg39) were
removed from the structure, and these two loops were linked together with a peptide bond using
Maestro (Suite 2012: Maestro, version 9.3; Schrödinger). The modeled structures were prepared for
simulation by keeping the crystallographic waters within 4.0 Å of any protein atom but removing the
buffer salts from the coordinate ﬁle. Next, hydrogen atoms were added to the structure using Protein
Preparation Tool from Schrödinger (26), and the optimal protonation states for the ionizable side chains
were determined. The hydrogen bonding network of the initial structures was optimized, and by using
the Impact reﬁnement module with the OPLS2005 force ﬁeld, the structures were minimized in vacuum
(27). Using the System Builder utility, these prepared systems were then solvated with the TIP3P water
model extending 10 Å beyond the protein in all directions in a truncated octahedron solvent box. The
overall charge of the system was neutralized by adding counter ions (Na or Cl). Desmond was used
in all simulations with the OPLS2005 force ﬁeld. Each simulation was carried out at 300 K and 105 Pa (
1 atm) for 100 ns, and the coordinates and energies were recorded every 5 ps.
Structural analysis. The hydrogen bonds were determined using VMD (28). A hydrogen bond
was deﬁned by the donor and acceptor distance less than 3 Å and a donor-hydrogen-acceptor angle
of 150°. To calculate the vdW contact energies between cyclic peptides and protease, a simpliﬁed
Lennard-Jones potential was applied, as described in detail before (29).
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